Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID RP ALMEIDA

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1437590718
CMS profile
631878
Location
ERIE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$186,737.63

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID RP ALMEIDA

NPI 1437590718 · CMS profile ID 631878

Allopathic & Osteopathic Physicians / Ophthalmology

ERIE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $186,737.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
F. Hoffmann-La Roche AG $701.5301/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345079 CMS
F. Hoffmann-La Roche AG $50.0301/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345085 CMS
Hoffmann-La Roche Limited $9,240.0001/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345091 CMS
Hoffmann-La Roche Limited $406.7701/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345099 CMS
Hoffmann-La Roche Limited $22.7701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345105 CMS
Hoffmann-La Roche Limited $884.3101/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040345111 CMS
Carl Zeiss Meditec, Inc. $975.0001/23/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059458895 CMS
Dutch Ophthalmic Research Center (International) B.V. $27.0201/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060585427 CMS
Dutch Ophthalmic Research Center (International) B.V. $41.0701/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060585431 CMS
Dutch Ophthalmic Research Center (International) B.V. $162.1401/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060585435 CMS
Dutch Ophthalmic Research Center (International) B.V. $50.2601/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060585439 CMS
Dutch Ophthalmic Research Center (International) B.V. $37.8301/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060585423 CMS
Dutch Ophthalmic, USA $7,441.5501/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050671837 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137,236.93 121
PY2020 $60,647.55 57
PY2021 $74,915.32 62
PY2022 $88,701.27 74
PY2023 $186,737.63 113
PY2024 $117,588.61 107
PY2025 $68,643.53 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,328.68 1
PY2025 Principal investigator $1,572,271.86 430
PY2024 Recipient $23,891.40 6
PY2024 Principal investigator $1,357,830.89 181
PY2023 Recipient $66,018.96 1
PY2023 Principal investigator $1,639,504.79 98
PY2022 Principal investigator $509,331.30 14
PY2021 Principal investigator $518,433.81 10
PY2020 Principal investigator $16,669.14 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

431 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche TCRC, Inc. $23,617.00 12/31/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211595695
Principal investigator 1 Ocular Therapeutix, Inc. $9,139.10 12/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233614
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 12/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175418126
Principal investigator 1 Ocular Therapeutix, Inc. $7,642.80 12/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233609
Principal investigator 1 ARGENX US, INC. $3,633.46 12/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149909
Principal investigator 1 Genentech, Inc. $63,891.00 12/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211603974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,418.20 12/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278024
Principal investigator 1 Astellas Pharma Global Development $900.00 12/18/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182941
Principal investigator 1 Astellas Pharma Global Development $3,000.00 12/18/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182947
Principal investigator 1 Roche TCRC, Inc. $500.00 12/18/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211595692
Principal investigator 1 Roche TCRC, Inc. $3,250.00 12/17/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211664299
Principal investigator 1 Janssen Research & Development, LLC $2,050.00 12/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418096
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Eerie Retina Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 12/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 12/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 12/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275493
Principal investigator 1 Ocular Therapeutix, Inc. $9,244.80 12/12/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233605
Principal investigator 1 ARGENX US, INC. $27,841.70 12/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149885
Principal investigator 1 Hoffmann-La Roche Limited $18,328.00 12/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211604012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $137.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $383.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $205.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $383.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $137.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $137.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $137.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $233.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $205.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,215.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $205.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $383.60 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.40 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $205.80 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.20 12/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184268611
Principal investigator 1 ARGENX US, INC. $53.00 12/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149859
Principal investigator 1 ARGENX US, INC. $441.00 12/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149862
Principal investigator 1 ARGENX US, INC. $2,026.89 11/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149898
Principal investigator 1 ARGENX US, INC. $5,303.14 11/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149901
Principal investigator 1 ARGENX US, INC. $1,528.94 11/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149906
Principal investigator 1 Astellas Pharma Global Development $573.00 11/24/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182943
Principal investigator 1 Astellas Pharma Global Development $573.00 11/24/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182949
Principal investigator 1 Ocular Therapeutix, Inc. $17,370.00 11/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233602
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603841
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603846
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603849
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603853
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603858
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 11/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603861
Principal investigator 1 Genentech, Inc. $6,468.00 11/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
iAMD Observational Study No dispute reported 06/30/2026 1211603967
Principal investigator 1 Ocular Therapeutix, Inc. $15,285.60 11/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,603.32 11/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261807
Principal investigator 1 ABBVIE INC. $20,280.00 11/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202522903
Principal investigator 1 Genentech, Inc. $210.00 11/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
iAMD Observational Study No dispute reported 06/30/2026 1211603963
Principal investigator 1 Genentech, Inc. $117,381.00 11/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603971
Principal investigator 1 Hoffmann-La Roche Limited $12,358.00 11/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211604003
Principal investigator 1 ABBVIE INC. $4,115.49 11/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202520065
Principal investigator 1 Hoffmann-La Roche Limited $47,996.00 11/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211604008
Principal investigator 1 Janssen Research & Development, LLC $4,348.00 11/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175418084
Principal investigator 1 ARGENX US, INC. $441.00 11/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149871
Principal investigator 1 ARGENX US, INC. $53.00 11/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149880
Principal investigator 1 Ocular Therapeutix, Inc. $6,896.00 10/31/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233593
Principal investigator 1 ABBVIE INC. $3,519.10 10/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202519585
Principal investigator 1 ARGENX US, INC. $2,651.57 10/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149893
Principal investigator 1 Ocular Therapeutix, Inc. $44,314.20 10/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233590
Principal investigator 1 Janssen Research & Development, LLC $2,648.00 10/27/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175418088
Principal investigator 1 Amgen Inc. $25,200.00 10/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC DAVID ALMEIDA
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246641283
Principal investigator 1 ARGENX US, INC. $23,787.45 10/23/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149890
Principal investigator 1 ARGENX US, INC. $1,220.35 10/23/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149913
Principal investigator 1 Ocular Therapeutix, Inc. $570.00 10/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233585
Principal investigator 1 Ocular Therapeutix, Inc. $1,065.00 10/17/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,418.20 10/17/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,418.20 10/17/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251189
Principal investigator 1 Ocular Therapeutix, Inc. $5,400.00 10/15/2025 Non-covered Recipient Entity
Eerie Retina Research
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233254
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233619
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603723
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603732
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603740
Principal investigator 1 Ocular Therapeutix, Inc. $12,137.40 10/08/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233575
Principal investigator 1 Roche TCRC, Inc. $23,538.00 10/07/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211595687
Principal investigator 1 Janssen Research & Development, LLC $4,813.00 10/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175418102
Principal investigator 1 Astellas Pharma Global Development $1,731.00 10/02/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182945
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603628
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603631
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603635
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603639
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603643
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603647
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603651
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603656
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603660
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603664
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603668
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603672
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603677
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603681
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603685
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603688
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603693
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603696
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603700
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603703
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603707
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603711
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603715
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603719
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603728
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603736
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603743
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603749
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603754
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603758
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603762
Principal investigator 1 F. Hoffmann-La Roche AG $317.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603767
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603771
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603775
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603778
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603782
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603785
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603789
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603793
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603796
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603801
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603805
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603810
Principal investigator 1 F. Hoffmann-La Roche AG $1,376.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603814
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603819
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603824
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603828
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603832
Principal investigator 1 F. Hoffmann-La Roche AG $338.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603837
Principal investigator 1 Janssen Research & Development, LLC $1,242.00 10/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418077
Principal investigator 1 ARGENX US, INC. $441.00 10/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149866
Principal investigator 1 ARGENX US, INC. $53.00 10/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149876
Principal investigator 1 Ocular Therapeutix, Inc. $11,691.90 10/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233567
Principal investigator 1 Ocular Therapeutix, Inc. $1,110.00 10/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233571
Principal investigator 1 Hoffmann-La Roche Limited $7,446.00 09/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603981
Principal investigator 1 Hoffmann-La Roche Limited $7,513.00 09/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603994
Principal investigator 1 Hoffmann-La Roche Limited $7,207.00 09/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603999
Principal investigator 1 Ocular Therapeutix, Inc. $570.00 09/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233563
Principal investigator 1 ARGENX US, INC. $1,220.35 09/18/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149916
Principal investigator 1 ARGENX US, INC. $9,398.09 09/18/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149919
Principal investigator 1 Genentech, Inc. $500.00 09/12/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664349
Principal investigator 1 Ocular Therapeutix, Inc. $952.00 09/12/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,219.72 09/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235913
Principal investigator 1 Ocular Therapeutix, Inc. $1,275.00 09/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233548
Principal investigator 1 Ocular Therapeutix, Inc. $1,781.20 09/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233552
Principal investigator 1 Ocular Therapeutix, Inc. $1,420.00 09/10/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233555
Principal investigator 1 Janssen Research & Development, LLC $920.00 09/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418173
Principal investigator 1 Amgen Inc. $27,375.00 09/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneous Teprotumumab in Participants with Active Moderate-to-Severe Thyroid Eye Disease No dispute reported 06/30/2026 1246641285
Principal investigator 1 Genentech, Inc. $17,089.00 09/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603911
Principal investigator 1 Ocular Therapeutix, Inc. $14,224.00 09/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233544
Principal investigator 1 ARGENX US, INC. $53.00 09/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149836
Principal investigator 1 ARGENX US, INC. $441.00 09/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149855
Principal investigator 1 Ocular Therapeutix, Inc. $850.00 08/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233534
Principal investigator 1 Ocular Therapeutix, Inc. $3,675.60 08/29/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233540
Principal investigator 1 Janssen Research & Development, LLC $5,854.65 08/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,418.20 08/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 08/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 08/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $679.00 08/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232139
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603580
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603583
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603600
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603612
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603617
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603620
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 08/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603624
Principal investigator 1 ARGENX US, INC. $30,824.33 08/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149923
Principal investigator 1 Janssen Research & Development, LLC $4,356.00 08/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418061
Principal investigator 1 Genentech, Inc. $177.00 08/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603897
Principal investigator 1 Genentech, Inc. $15,517.00 08/15/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603955
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182923
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182925
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182929
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182931
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182933
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182935
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182937
Principal investigator 1 Astellas Pharma Global Development $1,731.00 08/14/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182939
Principal investigator 1 Ocular Therapeutix, Inc. $1,831.20 08/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233526
Principal investigator 1 Ocular Therapeutix, Inc. $645.00 08/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233530
Principal investigator 1 Astellas Pharma Global Development $13,000.00 08/11/2025 Non-covered Recipient Entity
Erie Retina Research LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234182927
Principal investigator 1 Janssen Research & Development, LLC $1,600.00 08/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418073
Principal investigator 1 ABBVIE INC. $11,299.49 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202503595
Principal investigator 1 Genentech, Inc. $177.00 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603922
Principal investigator 1 Genentech, Inc. $7,229.00 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603933
Principal investigator 1 Genentech, Inc. $11,508.00 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603937
Principal investigator 1 Ocular Therapeutix, Inc. $21,468.60 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233518
Principal investigator 1 Ocular Therapeutix, Inc. $14,376.60 08/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233522
Principal investigator 1 ARGENX US, INC. $441.00 08/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149839
Principal investigator 1 ARGENX US, INC. $53.00 08/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149843
Principal investigator 1 Genentech, Inc. $26,571.00 08/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603926
Principal investigator 1 ANI Pharmaceuticals, Inc. $4,482.30 07/31/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567353
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,120.50 07/31/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567557
Principal investigator 1 Janssen Research & Development, LLC $930.00 07/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175418113
Principal investigator 1 Genentech, Inc. $1,133.00 07/25/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664358
Principal investigator 1 Janssen Research & Development, LLC $3,400.00 07/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418161
Principal investigator 1 Ocular Therapeutix, Inc. $14,212.80 07/25/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $679.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.00 07/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218489
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,120.60 07/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567361
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,120.60 07/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567375
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,121.02 07/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567421
Principal investigator 1 ANI Pharmaceuticals, Inc. $2,241.10 07/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567477
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,120.60 07/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567527
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 07/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603587
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 07/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603591
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 07/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603596
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 07/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603604
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 07/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211603608
Principal investigator 1 Genentech, Inc. $5,736.00 07/18/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664362
Principal investigator 1 Genentech, Inc. $444.00 07/16/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664367
Principal investigator 1 Ocular Therapeutix, Inc. $795.00 07/16/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 07/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 07/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 07/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.00 07/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214934
Principal investigator 1 Genentech, Inc. $3,016.00 07/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603906
Principal investigator 1 Genentech, Inc. $2,500.00 07/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603918
Principal investigator 1 Genentech, Inc. $9,923.00 07/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603942
Principal investigator 1 Genentech, Inc. $2,646.00 07/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211603959
Principal investigator 1 Ocular Therapeutix, Inc. $1,082.00 07/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,313.92 07/09/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213417
Principal investigator 1 Roche TCRC, Inc. $13,467.70 07/08/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211595684
Principal investigator 1 Ocular Therapeutix, Inc. $3,162.00 07/04/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233500
Principal investigator 1 Genentech, Inc. $3,779.00 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603902
Principal investigator 1 Genentech, Inc. $1,763.00 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603915
Principal investigator 1 Genentech, Inc. $10,769.00 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603929
Principal investigator 1 Genentech, Inc. $3,024.00 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603947
Principal investigator 1 Genentech, Inc. $1,988.00 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603951
Principal investigator 1 Ocular Therapeutix, Inc. $15,764.40 07/02/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233496
Principal investigator 1 ARGENX US, INC. $441.00 07/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149847
Principal investigator 1 ARGENX US, INC. $53.00 07/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149851
Principal investigator 1 Hoffmann-La Roche Limited $13,525.50 07/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603977
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 07/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603986
Principal investigator 1 Hoffmann-La Roche Limited $1,544.00 07/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled No dispute reported 06/30/2026 1211603990
Recipient Ocular Therapeutix, Inc. $11,328.68 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229227
Principal investigator 1 Roche TCRC, Inc. $224.57 06/30/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211595680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,380.72 06/27/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,579.52 06/27/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,192.60 06/27/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184210974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184210976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 06/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211553
Principal investigator 1 Janssen Research & Development, LLC $8,264.65 06/09/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418157
Principal investigator 1 Janssen Research & Development, LLC $1,568.00 06/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418179
Principal investigator 1 ARGENX US, INC. $161.70 06/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149826
Principal investigator 1 ARGENX US, INC. $13.40 06/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149829
Principal investigator 1 ARGENX US, INC. $19.43 06/01/2025 Non-covered Recipient Entity
Erie Retina Research
A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease No dispute reported 06/30/2026 1237149833
Principal investigator 1 Ocular Therapeutix, Inc. $20,350.80 05/30/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233468
Principal investigator 1 Ocular Therapeutix, Inc. $14,264.10 05/30/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233472
Principal investigator 1 Ocular Therapeutix, Inc. $12,088.80 05/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233465
Principal investigator 1 Amgen Inc. $4,738.49 05/27/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246641287
Principal investigator 1 Ocular Therapeutix, Inc. $2,248.00 05/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233462
Principal investigator 1 ANI Pharmaceuticals, Inc. $25,296.70 05/15/2025 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
New Day Study No dispute reported 06/30/2026 1248567521
Principal investigator 1 Genentech, Inc. $316.00 05/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603882
Principal investigator 1 Roche TCRC, Inc. $42,656.00 05/13/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211595676
Principal investigator 1 Ocular Therapeutix, Inc. $825.00 05/09/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233458
Principal investigator 1 Genentech, Inc. $187.00 05/01/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664333
Principal investigator 1 Genentech, Inc. $2,948.40 05/01/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664337
Principal investigator 1 Ocular Therapeutix, Inc. $3,675.60 04/30/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233453
Principal investigator 1 Roche TCRC, Inc. $4,250.00 04/29/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211595672
Principal investigator 1 Genentech, Inc. $6,504.00 04/23/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603878
Principal investigator 1 Janssen Research & Development, LLC $610.00 04/17/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418054
Principal investigator 1 Janssen Research & Development, LLC $8,466.00 04/11/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418067
Principal investigator 1 Roche TCRC, Inc. $2,031.00 04/08/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211664294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 04/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 04/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 04/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 04/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 04/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184181880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $120.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $384.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 04/01/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184180498
Principal investigator 1 Janssen Research & Development, LLC $5,776.00 03/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418119
Principal investigator 1 Ocular Therapeutix, Inc. $19,726.20 03/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233493
Principal investigator 1 Ocular Therapeutix, Inc. $18,154.55 03/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233489
Principal investigator 1 Ocular Therapeutix, Inc. $900.00 03/14/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233484
Principal investigator 1 Ocular Therapeutix, Inc. $5,473.00 03/07/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233481
Principal investigator 1 Janssen Research & Development, LLC $1,076.00 03/06/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418167
Principal investigator 1 Ocular Therapeutix, Inc. $55,648.80 03/05/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233477
Principal investigator 1 Janssen Research & Development, LLC $19,825.95 03/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418042
Principal investigator 1 Janssen Research & Development, LLC $1,076.00 03/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418137
Principal investigator 1 Ocular Therapeutix, Inc. $5,513.40 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,500.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 02/26/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion No dispute reported 06/30/2026 1184155716
Principal investigator 1 Janssen Research & Development, LLC $3,978.00 02/21/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418132
Principal investigator 1 Amgen Inc. $22,350.00 02/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246641289
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595559
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595563
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595566
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595570
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595573
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595577
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595581
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595585
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595589
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595594
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595597
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595602
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595605
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595610
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595614
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595618
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595623
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595628
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595632
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595636
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595640
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595644
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595650
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595656
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595660
Principal investigator 1 F. Hoffmann-La Roche AG $281.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595663
Principal investigator 1 F. Hoffmann-La Roche AG $110.00 02/19/2025 Non-covered Recipient Entity
David Almeida D/B/A Erie Retina Research
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211595668
Principal investigator 1 Genentech, Inc. $875.00 02/19/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211603885
Principal investigator 1 Janssen Research & Development, LLC $1,076.00 02/17/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175418150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,500.00 02/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184153890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,835.00 02/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184153892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,725.00 02/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184153894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 02/13/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184153896
Principal investigator 1 Genentech, Inc. $13,616.00 02/12/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211603894
Principal investigator 1 Ocular Therapeutix, Inc. $1,480.00 02/12/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233441
Principal investigator 1 Genentech, Inc. $8,486.00 02/05/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664327
Principal investigator 1 Genentech, Inc. $971.00 02/05/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
iAMD Observational Study No dispute reported 06/30/2026 1211664330
Principal investigator 1 Janssen Research & Development, LLC $2,580.00 02/03/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418107
Principal investigator 1 Genentech, Inc. $813.00 01/28/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA No dispute reported 06/30/2026 1211603890
Principal investigator 1 Ocular Therapeutix, Inc. $22,053.60 01/24/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250233445
Principal investigator 1 Genentech, Inc. $4,403.00 01/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603865
Principal investigator 1 Genentech, Inc. $18,460.00 01/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603869
Principal investigator 1 Genentech, Inc. $3,024.00 01/22/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH LLC
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211603873
Principal investigator 1 Roche TCRC, Inc. $7,872.00 01/21/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211664291
Principal investigator 1 Janssen Research & Development, LLC $3,390.00 01/20/2025 Non-covered Recipient Entity
ERIE RETINA RESEARCH
A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound No dispute reported 06/30/2026 1175418048
Principal investigator 1 ANI Pharmaceuticals, Inc. $1,120.60 01/17/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
The SYNCHRONICITY Study No dispute reported 06/30/2026 1248567357